The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia.

Lukáš KonečnýMarcel HrubšaJana KarlíčkováAlejandro CarazoLenka JavorskáKateřina MatoušováLenka Kujovská KrčmováVladimír BlahaMilan BláhaPřemysl Mladěnka

Published in: Cardiovascular drugs and therapy (2023)

This study showed for the first time the suitability of PCSK9ab treatment for reduction of platelet reactivity in FH patients.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
smoking cessation